Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearyl Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8846467 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| Hexyl Fumarate SCHEMBL11528189 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL11798238 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL8846967 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL8846477 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL8846972 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL10732344 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL10733209 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| SCHEMBL11799348 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A | |
| Stearyl Fumaric Acid SCHEMBL10731307 | 1.00 | HCAR2 (0.69) | HCAR2ATMAPPMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408026-A1 | COMPOSITION COMPRISING GELATIN, GELATIN FILMS AND CAPSULES | TESSENDERLO GROUP NV (BE) | 2024-12-12 | — | — | US | claimed |
| EP-4419076-A1 | COMPOSITION COMPRISING GELATIN, GELATIN FILMS AND CAPSULES | Tessenderlo Group NV (BE) | 2024-08-28 | — | — | EP | claimed |
| CN-118284404-A | Composition comprising gelatin, gelatin film and capsule | 泰森德洛集团公司 | 2024-07-02 | — | — | CN | claimed |
| WO-2023067092-A1 | COMPOSITION COMPRISING GELATIN, GELATIN FILMS AND CAPSULES | TESSENDERLO GROUP NV (BE) | 2023-04-27 | — | — | WO | claimed |
| EP-4169503-A1 | COMPOSITION COMPRISING GELATIN, GELATIN FILMS AND CAPSULES | Tessenderlo Group NV (BE) | 2023-04-26 | — | — | EP | claimed |
| CN-112336695-A | Propofol fumarate and tenofovir tablet, preparation method thereof and detection method of related substances | 华北制药华坤河北生物技术有限公司 | 2021-02-09 | — | — | CN | claimed |
| WO-2018142334-A1 | FORMULATIONS COMPRISING OXALATE SALTS OF TENELIGLIPTIN AND SOLVATES THEREOF | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2018-08-09 | — | — | WO | claimed |
| CN-115427076-B | Human deubiquitinase inhibitors for the treatment of coronavirus infections | 免疫学有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-116075306-B | Compounds for the treatment of coronavirus infections | 麦翠奥制药公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240408026-A1 | COMPOSITION COMPRISING GELATIN, GELATIN FILMS AND CAPSULES | TESSENDERLO GROUP NV (BE) | 2024-12-12 | — | — | US | disclosed |
| CN-118973563-A | Combination of 5-amino-2, 3-dihydro-1, 4-phthalazinedione with fumarate | 麦翠奥制药公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118785909-A | Use of 5-amino-2, 3-dihydro-1, 4-phthalazinediones for the treatment of congenital muscular dystrophy | 麦翠奥制药公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4419076-A1 | COMPOSITION COMPRISING GELATIN, GELATIN FILMS AND CAPSULES | Tessenderlo Group NV (BE) | 2024-08-28 | — | — | EP | disclosed |
| US-20110159087-A1 | Crosslinked Polymers | USV LIMITED (IN) | 2011-06-30 | — | — | US | disclosed |
| US-7846425-B2 | Process for the preparation of sevelamer hydrochloride and formulation thereof | USV, LTD. (IN) | 2010-12-07 | — | — | US | disclosed |
| US-20100092421-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | USV PRIVATE LIMITED (IN) | 2010-04-15 | — | — | US | disclosed |
| WO-2010041268-A2 | CROSSLINKED POLYMERS | USV LIMITED (IN) | 2010-04-15 | — | — | WO | disclosed |
| US-20090280178-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | USV PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| EP-2064252-A2 | PROCESS FOR THE PREPARATION OF SEVELAMER HYDROCHLORIDE AND FORMULATION THEREOF | USV LIMITED (IN) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008062437-A2 | PROCESS FOR THE PREPARATION OF SEVELAMER HYDROCHLORIDE AND FORMULATION THEREOF | USV LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408026-A1 | COMPOSITION COMPRISING GELATIN, GELATIN FILMS AND CAPSULES | S100P, S100A4, S100A10 | HCAR2 1232/4885ATM 4624/4885APP 2017/4885 |
| US-20100092421-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | DPP4, PDE9A, SI | HCAR2 4479/4885ATM 1906/4885APP 3369/4885 |
| US-20090280178-A1 | Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof | DPP4, PDE9A, SI | HCAR2 4479/4885ATM 1906/4885APP 3369/4885 |
| US-20110159087-A1 | Crosslinked Polymers | SLC10A1, CETP, SLC10A2 | HCAR2 1665/4885ATM 3882/4885APP 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.